DAFNA Capital Management LLC Has $6.88 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

DAFNA Capital Management LLC increased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 12.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 811,678 shares of the specialty pharmaceutical company's stock after purchasing an additional 88,000 shares during the period. KalVista Pharmaceuticals makes up 1.7% of DAFNA Capital Management LLC's investment portfolio, making the stock its 18th largest holding. DAFNA Capital Management LLC owned about 1.64% of KalVista Pharmaceuticals worth $6,875,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after acquiring an additional 1,319 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. grew its position in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after buying an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after buying an additional 2,043 shares during the last quarter. Finally, AlphaQuest LLC raised its position in KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares during the period.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $12.25 on Thursday. The company has a market capitalization of $609.02 million, a price-to-earnings ratio of -3.37 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The business has a 50 day moving average of $12.00 and a 200 day moving average of $10.43.

Analysts Set New Price Targets

A number of research firms recently weighed in on KALV. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective for the company. Jones Trading reiterated a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $24.83.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now directly owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par purchased 4,137 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were acquired at an average price of $9.14 per share, for a total transaction of $37,812.18. Following the acquisition, the insider now owns 5,090,582 shares in the company, valued at $46,527,919.48. This trade represents a 0.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 202,786 shares of company stock valued at $1,880,511 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.